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Abstract 
Background: Integrins are expressed in tumor cells and tumor endothelial cells, and likely 
play important roles in glioma angiogenesis and invasion.  
Objective: We investigated the anti-glioma mechanisms of cilengitide (EMD121974), an 
αvβ3 integrin inhibitor, utilizing the novel invasive glioma models, J3T-1and J3T-2.  
Methods and results: Immunohistochemical staining of cells in culture and brain tumors in 
rats revealed positive αvβ3 integrin expression in J3T-2 cells and tumor endothelial cells, but 
not in J3T-1 cells. Established J3T-1 and J3T-2 orthotopic gliomas in athymic rats were 
treated with cilengitide or solvent. J3T-1 gliomas showed perivascular tumor cluster 
formation and angiogenesis, while J3T-2 gliomas showed diffuse single-cell infiltration 
without obvious angiogenesis. Cilengitide treatment resulted in a significantly decreased 
diameter of the J3T-1 tumor vessel clusters and its core vessels when compared with controls, 
while an anti-invasive effect was shown in the J3T-2 glioma with a significant reduction of 
diffuse cell infiltration around the tumor center. The survival of cilengitide-treated mice 
harboring J3T-1 tumors was significantly longer than that of control animals (median 
survival; 57.5 days and 31.8 days, respectively, P < 0.005), while cilengitide had no effect on 
the survival of mice with J3T-2 tumors (median survival; 48.9 days and 48.5, P = 0.69).  
Conclusion: Our results indicate that cilengitide exerts a phenotypic anti-tumor effect by 
inhibiting angiogenesis and glioma cell invasion. These two mechanisms are clearly shown 
by the experimental treatment of two different animal invasive glioma models.  
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Introduction 
Gliomas are the most frequent primary intracranial neoplasm in adults, and are invariably 
fatal. The median survival of aggressively treated patients with glioblastoma multiforme 
(GBM) is approximately 14.6 months1. The resistance of gliomas to the conventional 
therapeutic regimen of surgery, radiotherapy, and chemotherapy has prompted many 
investigators to seek novel therapeutic approaches for this fatal disease2. 
Two major aspects of glioma biology are the formation of new blood vessels through 
angiogenesis and the invasion of glioma cells via white matter tracts, which are the hallmarks 
of GBM3. The formation of abnormal tumor vasculature is one of the major reasons for the 
resistance of these tumors to treatment4. Inhibitors of angiogenesis can suppress tumor 
growth in preclinical models and have entered the clinic as prospective anticancer 
therapeutics5. Specifically, the administration of bevacizumab, a humanized monoclonal 
antibody against vascular endothelial growth factor (VEGF), in combination with irinotecan, 
a topoisomerase inhibitor, significantly improves outcome among recurrent patients6,7. 
However, de Groot et al.8 showed that glioma cases developed an apparent phenotypic shift 
to a predominantly infiltrative pattern of tumor progression after treatment with bevacizumab. 
Thus, in addition to anti-angiogenesis therapy, successful treatment strategies for GBM may 
require the concomitant targeting of tumor cell invasion9. 
Integrins are expressed in tumor cells and tumor endothelial cells10, and they play 
important roles in angiogenesis and invasion in gliomas11-13. αvβ3 and αvβ5 integrins regulate 
cell adhesion14,15, and inhibitors of these integrins suppress tumor growth in certain 
pre-clinical models16. Therefore, integrins are being investigated as therapeutic targets in 
gliomas. 
Cilengitide (EMD121974), a cyclic arginine-glycine-aspartic acid pentapeptide, is an 
αvβ3 integrin antagonist that induces anoikis in angiogenic blood vessels and brain tumor 
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cells in vitro17,18. Cilengitide may inhibit tumor growth by at least two mechanisms: by 
targeting the tumor cells directly and by inhibiting tumor angiogenesis2,17,19. However, these 
mechanisms were not elucidated in invasive brain tumor models in animals. 
We have established two new cell line-based animal models of invasive glioma, J3T-1 
and J3T-2. These animal models histologically recapitulate two invasive and angiogenic 
phenotypes, namely angiogenesis-dependent and -independent invasion, which is also 
observed in human glioblastoma4,20. In short, J3T-1 cells form well demarcated and highly 
angiogenic tumors in rat brains, and clusters of tumor cells are seen around dilated, newly 
developed vessels in the adjacent normal brain. Therefore, J3T-1 gliomas express 
angiogenesis-dependent invasion and growth. In contrast, J3T-2 cells form poorly demarcated 
tumors, where the tumor cells gradually disperse from the tumor center to the normal brain 
parenchyma. Single cells also invade the normal brain parenchyma along white matter tracts. 
Therefore, J3T-2 gliomas express angiogenesis-independent invasion and growth. 
To our knowledge, there are no published data demonstrating the anti-angiogenic or 
anti-invasive effects of cilengitide on gliomas using invasive animal models. Investigating the 
effects of cilengitide poses a challenge because most of the conventional animal models fail 
to mimic the invasiveness and angiogenesis of human glioma. Here, we investigated the 
antitumor effects of cilengitide on two experimental animal models of malignant glioma, 
J3T-1 and J3T-2.  
 
Materials and Methods  
Glioma cell lines 
Two cell lines, J3T-1 and J3T-2, were developed from the same parental J3T canine glioma 
cell line (a generous gift from Dr. Michael E. Berens; Translation Genomics Research 
Institute, Phoenix, AZ, USA), as previously described4,21. J3T-1 cells and J3T-2 cells were 
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seeded on tissue culture dishes (BD Falcon, Franklin Lakes, NJ, USA) and cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS), 100 units of penicillin and 0.1 mg of streptomycin per milliliter.  
 
Cell surface immunofluorescence assay 
J3T-1 and J3T-2 cells were seeded onto four chamber polystyrene vessel tissue culture 
treated glass slides (BD Falcon) and incubated overnight. For immunofluorescence, the cells 
were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 15 min. After the 
cells were fixed, they were rinsed three times with PBS. Nonspecific binding was blocked by 
incubation in a blocking buffer containing 2% bovine serum albumin (BSA) in PBS for 30 
min at room temperature. The cells were incubated overnight at 4°C with a mouse 
monoclonal anti-αvβ3 integrin antibody (Millipore Corporation, Billerica, MA, USA) diluted 
1:100 in blocking buffer. The cells were washed three times in blocking buffer for 5 min 
before incubation with a secondary anti-mouse CY3-conjugated antibody (Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA, USA) diluted 1:300 in blocking buffer 
for 2 h at room temperature in the dark. After three washes in PBS, the cells were 
counterstained with 4′, 6-diamino-2-phenylindole (DAPI; 1:500) (Invitrogen, Carlsbad, CA, 
USA) (100 ng/mL) for 20 min at room temperature. The slides were washed three times in 
PBS and mounted. 
 
Tube formation assay 
An angiogenesis assay kit (Kurabo, Osaka, Japan) was used according to the 
manufacturer’s instructions. Briefly, human umbilical vein endothelial cells (HUVECs), 
co-cultured with neonatal normal human dermal fibroblasts (NHDFs)22, were treated with 
various concentrations of cilengitide (0, 0.1, 0.5, or 1.0, or 2.0 μM) and VEGF (10 ng/mL) 
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added to the medium. Cilengitide was generously provided by Merck Serono and the 
National Cancer Institute, NIH. Suramin (50 μM) was used as a positive anti-angiogenic 
control. The medium was changed every three days. After ten days, the dishes were washed 
with PBS and fixed with 70% ethanol at 4°C. After the fixed cells were rinsed three times 
with PBS, the cells were incubated with mouse anti-human CD31 antibody (Kurabo, Osaka, 
Japan) diluted 1:4000 in PBS containing 1% BSA for 60 min. After washing three times with 
1% BSA-PBS, the cells were incubated with goat anti-mouse IgG-alkaline phosphatase 
conjugate. Metal-enhanced 3, 3′-diamino-benzidine-tetrahydrochloride (DAB) was used as 
the substrate with the reaction yielding a dark reddish-brown insoluble end-product. Finally, 
the cells were washed five times with PBS and viewed under a microscope (BZ-8000, 
Keyence, Osaka, Japan). The area and tube length were measured quantitatively with the 
Kurabo angiogenesis image analyzer in five different fields per well and statistically 
analyzed23.  
 
Effects of cilengitide on cultured glioma cells  
J3T-1 and J3T-2 cells were seeded on 6 well plates (1.0×104 cells/well) and cultured in 
DMEM supplemented with 10% FBS. Cilengitide (0, 0.1, 0.5, or 1.0 μM) was added to the 
medium after 24 h of incubation. Each experiment was performed in triplicate. After 
incubation for 120 h at 37°C, the cells were examined for morphological changes. 
Non-adherent cells were removed by gentle washing twice with PBS, and the attached cells 
were then trypsinized and counted. The cell counts at 24 and 120 h incubation were compared 
and the cell proliferation rate was calculated17. Apoptotic cells were detected with the In Situ 
Cell Death Detection Kit (Roche, Basel, Switzerland) according to the manufacturer’s 
instructions.  
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Invasive glioma xenograft models  
All experimental animals were housed and handled in accordance with the guidelines of the 
Okayama University Animal Research Committee. Before implantation, 85–90% confluent 
J3T-1 and J3T-2 cells were trypsinized, rinsed with DMEM supplemented with 10% FBS, 
and centrifuged at 100×g for 5 min. The resulting pellet was then resuspended in PBS, and 
the cell concentration was adjusted to 1.0×105 cells/μL. For each cell line, athymic rats 
(F344/N-nu/nu; CLEA Japan, Inc., Tokyo, Japan) were injected with 5 μL J3T-1 or J3T-2 
cells and athymic mice (balb/c-nu/nu; CLEA Japan, Inc, Tokyo, Japan) were injected with 2 
μL J3T-1 or J3T-2 cells. The animals were anesthetized and placed in stereotactic frames 
(Narishige, Tokyo, Japan) with their skulls exposed. Tumor cells were injected with a 
Hamilton syringe (Hamilton, Reno, NV, USA) into the right frontal lobe (in the athymic rats: 
4 mm lateral and 1 mm posterior to the bregma at a depth of 4 mm; in the athymic mice: 3 
mm lateral and 1 mm anterior to the bregma at a depth of 3 mm), and the syringe was slowly 
withdrawn after 5 min to prevent reflux. The skulls were then cleaned, the holes were sealed 
with bone wax, and the incision was sutured.  
Cilengitide or PBS was administered three times/week intraperitoneally (for the 
athymic mouse: 200 μg/100 μL PBS; for the athymic rat: 1000 μg/500 μL PBS) starting on 
day five after tumor cell implantation. To analyze survival time, the J3T-1 and J3T-2 athymic 
mice xenograft models were monitored. 
 
Histopathological analysis of glioma in rats  
For histopathological analysis, athymic rats harboring J3T-1 or J3T-2 brain tumors 
were sacrificed at 35 days after tumor implantation. Before being sacrificed for 
immunohistochemistry and hematoxylin and eosin (HE) staining, athymic rats were 
anesthetized, euthanized by cardiac puncture, perfused with 100 mL PBS, and fixed with 200 
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mL 4% paraformaldehyde. The brains were removed and stored in 4% paraformaldehyde for 
at least 24 h.  
For HE staining, the sections were immersed in hematoxylin for 1 min and rinsed 
with tap water. The sections were then immersed in an eosin stain for 1–2 min and rinsed 
with tap water. 
For immunohistochemical staining of αvβ3 integrin, after deparaffinization in xylene 
and rehydration in decreasing concentrations of ethanol, 4-μm thick sections were incubated 
in 0.3% H2O2 (30 min) and autoclaved for 10 min at 121°C in distilled water. After washing 
three times in PBS, the sections were incubated at room temperature for 1 h with a mouse 
monoclonal anti-αvβ3 integrin antibody (Millipore) diluted 1:100 in a solution of PBS and 
5% skimmed milk. The Dako Cytomation Envision+ System-HRP Kit was then applied 
according to the manufacturer’s protocol (DakoCytomation, Carpentaria, CA, USA). After 
three washes in PBS, the sections were counterstained with hematoxylin. 
For immunofluorescent staining, snap-frozen tissue samples were embedded in a 
compound of optimal cutting temperature for cryosectioning, and 16-μm cryostat sections 
were processed for indirect immunofluorescence. The slides were incubated with 10% horse 
serum in PBS at room temperature for 60 min, then overnight at 4°C with an anti-RECA-1 
antibody (Abcam, Cambridge, MA, USA) diluted 1:20 in 1% horse serum in PBS. After three 
washes with PBS for 5 min, the slides were incubated with a Cy3-conjugated anti-mouse 
antibody (Jackson ImmunoResearch Laboratories) and DAPI (1:500) (Invitrogen) in PBS for 
60 min. The slides were then washed in PBS and mounted. 
 
Statistical analysis 
The student’s t test was used to test for statistical significance. Data were presented as 
the means ± standard error. Kaplan–Meier curves were compared using the log-rank test. 
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Statistical analysis was performed using Stat View statistical software (version 5.0; SAS 
Institute Inc., Cary, NC, USA). 
 
Results 
Immunohistochemical analysis of αvβ3 integrin expression in the two glioma cell lines 
Immunofluorescence assays were conducted to determine the expression of αvβ3 
integrin in J3T-1 and J3T-2 cells. Cultured J3T-1 cells were not immunopositive for αvβ3 
integrin (Fig. 1A). In contrast, robust expression of αvβ3 integrin was observed on the surface 
of J3T-2 cells (Fig. 1B). 
Immunohistochemical staining for αvβ3 integrin was also performed in brain slices of 
animals harboring either J3T-1 or J3T-2 brain tumors. The J3T-1 glioma cells that were 
clustered around the dilated tumor vessels were negative for αvβ3 integrin, yet the endothelial 
cells of dilated tumor vessels were clearly positive for αvβ3 integrin (Fig. 1C). J3T-2 glioma 
cells were diffusely positive for αvβ3 integrin. There were no dilated vessels in the J3T-2 
tumors that were positive for αvβ3 integrin (Fig. 1D). 
 
Effects of cilengitide on endothelial cells in vitro 
To investigate the effects of cilengitide on endothelial cells, a tube formation assay using 
HUVECs co-cultured with NHDFs was performed. HUVECs formed tubes in the medium 
containing VEGF (Fig. 2A). The addition of cilengitide (0.1 μM, 0.5 μM, 1.0 μM) to the 
culture medium inhibited tube formation in a concentration-dependent manner (Fig. 2B–D). 
All HUVECs and NHDFs detached from the dishes when the concentration of cilengitide was 
2.0 μM. An anti-VEGF drug (suramin: 50 μM) also inhibited tube formation (Fig. 2E). The 
average tube length under each condition was computed (0 μM cilengitide: 1.45×104 ± 
4.9×102 pixels; 0.1 μM cilengitide: 1.24×104 ± 5.8×102 pixels; 0.5 μM cilengitide: 1.04×104 
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± 5.8×102 pixels; 1.0 μM cilengitide: 0.90×104 ± 4.8×102 pixels (P < 0.05); 50 μM suramin: 
0.99×104 ± 6.8×102 pixels) (Fig. 2F). Quantitative analysis of tube length confirmed that 
cilengitide inhibited angiogenesis in vitro in a concentration-dependent manner. 
 
Cytotoxic effects of cilengitide on the two invasive glioma cell lines in vitro 
The direct effects of cilengitide were investigated on glioma cells in vitro. J3T-1 
and J3T-2 cells were incubated with cilengitide at concentrations of 0–1.0 μM. Treated cells 
were examined for morphologic changes after 120 h. Originally, J3T-1 cells in culture were 
composed of bipolar cells and spherical cells. When the cells were incubated with cilengitide, 
the number of spherical cells increased in a dose-dependent manner (Fig. 3A). However, 
there was no significant increase in the number of detached cells. Before administration of 
cilengitide, J3T-2 cells were mostly composed of bipolar cells. They became spherical and 
agglutinated when cilengitide was added to the incubation media. Some of these deformed 
cells detached from the plate (Fig. 3A). The detached J3T-2 cells were not viable, as 
indicated by unsuccessful attempts of re-plating in media containing no cilengitide. To 
confirm the apoptosis of deformed glioma cells treated with cilengitide, cells were stained 
with the In Situ Cell Death Detection Kit using TMR red. J3T-1 cells were negative for 
apoptosis, while J3T-2 cell clusters were positive (Fig. 3B). 
The attached cell count was measured and compared between 24 and 120 h after 
incubation (Fig. 3C). The counts of J3T-1 cells did not change with any concentrations of 
cilengitide (0–1.0 μM), whereas the counts of J3T-2 cells decreased in a dose-dependent 
manner. The count of J3T-1 cells incubated with or without cilengitide (1.0 μM) increased by 
19.2-fold and 18.9-fold, respectively. The count of J3T-2 cells incubated with or without 
cilengitide increased by 13.2-fold and 19.6-fold, respectively. Therefore, cilengitide 
significantly inhibited the proliferation of J3T-2 cells (P < 0.05), but not J3T-1 cells (P = 
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0.992).  
 
Anti-angiogenic effects of cilengitide in the J3T-1 gliomas in rats 
Angiogenic activity was histopathologically evaluated using the J3T-1 
angiogenesis-dependent invasive glioma models in rats. Macroscopic examinations Low 
magnification of HE staining of J3T-1 control tumors revealed that J3T-1 cells formed 
clusters in the adjacent normal brain (Fig. 4A). Immunofluorescence staining (vascular 
endothelial cells: RECA-1, red; nuclei: DAPI, blue) of J3T-1 control tumors clearly showed 
this tumor’s angiogenesis-dependent invasive phenotype as described in a former study20. In 
short, J3T-1 cells were clustered, with these clusters centered on dilated neovascular vessels, 
and invaded along the perivascular area (Fig. 4C). When animals were treated with 
intraperitoneal cilengitide (n=3), brain tumors showed an angiogenesis-dependent pattern 
(Fig. 4B). There was no significant difference in the invasive pattern between 
cilengitide-treated and control tumors. However, the extent of spread of invasion clusters was 
significantly decreased in animals treated with cilengitide compared with the control animals. 
Furthermore, the diameter of the tumor clusters and its core vessels in the treated animals was 
smaller than that in the untreated animals (Fig. 4D).  
To quantify the effect of cilengitide, the diameter of the tumor clusters around the 
neovasculature and the diameter of the tumor vessels were measured with ImageJ software 
(http://rsb.info.nih.gov/ij). The diameter of tumor clusters in control and cilengitide-treated 
animals was 111 ± 6.4 μm and 86.3 ± 6.8 μm, respectively (P < 0.005) (Fig. 4E). The 
diameter of core vessels in control and treated animals was 16.3 ± 1.0 μm and 12.5× ± 1.0 μm, 
respectively (P < 0.005) (Fig. 4F).  
 
Anti-invasive effects of cilengitide demonstrated in the J3T-2 gliomas in rats 
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The effect of cilengitide on the diffuse invasive activity of glioma cells was 
histopathologically evaluated using J3T-2 angiogenesis-independent invasive glioma models 
in rats. Macroscopic examinations of HE staining of J3T-2 control tumors revealed that J3T-2 
tumors strongly invaded the adjacent normal brain (Fig. 5A). Briefly, tumor cells gradually 
dispersed from the tumor center to the normal brain parenchyma with a cell density gradient, 
which meant that J3T-2 cells formed poorly demarcated tumors. Minimal angiogenesis was 
seen with only a small number of slightly dilated vessels at the tumor center. A similar 
invasive pattern was observed in animals treated with cilengitide (n=3) (Fig. 5B). The merged 
immunofluorescence staining images (vascular endothelial cells: RECA-1, red; nuclei: DAPI, 
blue) revealed the tumor borders in more detail (Fig. 5C, D). The distribution area of diffuse 
tumor cell infiltration around the tumor center was smaller in cilengitide-treated animals 
compared with control animals. To quantify the cell density, the merged images from the 
J3T-2 tumor center to the normal subcortex, avoiding the corpus callosum, were partitioned 
into 22 equal areas (200 μm×100 μm), and the nuclei (DAPI, blue) in each area were counted 
(n=3). The cell density at the tumor center was significantly higher in treated animals than in 
control animals (Fig. 5E). The cell density of control tumors was gradually reduced from the 
tumor center toward the normal brain parenchyma, while the cell density of treated tumors 
dropped steeply at the tumor border. There were no significant differences in cell numbers in 
the designated areas (200 μm×2200 μm) (control tumors: 1400 ± 31 cells; treated tumors: 
1310 ± 72 cells; P = 0.27) (Fig. 5F).  
 
The cytotoxic effects of cilengitide on the J3T-1 and J3T-2 gliomas in rats 
The cytotoxic effects of cilengitide on glioma cells in vivo were investigated using both rat 
brain tumor models. A subpopulation of apoptotic cells were visualized by the TdT-mediated 
dUTP nick end labeling (TUNEL) treatment using the In Situ Cell Death Detection Kit 
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(apoptotic cells: TMR red; nuclei: DAPI, blue). The J3T-1 control tumor (Fig. 6A), J3T-1 
cilengitide treated tumor (Fig. 6B), J3T-2 control tumor (Fig. 6C), and J3T-2 cilengitide 
treated tumor (Fig. 6D) sections from rat brains were prepared and assayed. These figures 
show a low number (2-3%) of apoptotic cells. To quantify the cytotoxic effect of cilengitide, 
the number of apoptotic cells per high-power field (HPF) in J3T-1 tumors (Fig.6E) and J3T-2 
tumors (Fig.6F) were assessed. (J3T-1 control tumors: 5.75 ± 1.6 cells/HPF, J3T-1 cilengitide 
treated tumors: 3.71 ± 0.6 cells/HPF, J3T-2 control tumors: 4.50 ± 1.1 cells/HPF, J3T-2 
cilengitide treated tumors: 5.83 ± 1.1 cells/HPF). There was no significant difference in 
apoptotic cells in the cilengitide-treated tumors compared with control tumors (J3T-1, P = 
0.5972; J3T-2, P = 0.4233). 
 
Survival analysis by using two different invasive glioma models 
To evaluate the in vivo anti-tumor effect of cilengitide, the long-term survival of mice 
harboring J3T-1 or J3T-2 brain tumors was analyzed. Athymic mice harboring J3T-1 or 
J3T-2 brain tumors (12 animals each) were each divided into two groups. The animals 
received either intraperitoneal cilengitide (200 μg/100 μL, three times/week) or PBS. The 
median survival was 57.5 days in animals bearing J3T-1 tumors treated with cilengitide, and 
31.8 days in animals given PBS (Fig. 7A). A significant prolongation of survival by 
cilengitide administration was observed in animals harboring J3T-1 tumors (P < 0.005). In 
contrast, the survival of mice bearing J3T-2 gliomas was not prolonged by intraperitoneal 
cilengitide injection (P = 0.69) (Fig. 7B). The median survival of the animals with J3T-2 
tumors treated either with cilengitide or PBS was 48.9 days or 48.5 days, respectively. 
 
Discussion  
In the present study, we tested cilengitide on two invasive glioma animal models, J3T-1 
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(αvβ3 integrin-negative, angiogenesis-dependent invasive phenotype) and J3T-2 (αvβ3 
integrin-positive, angiogenesis-independent invasive phenotype). In vitro proliferation of 
αvβ3 integrin-positive J3T-2 cells was significantly inhibited by cilengitide, whereas 
cilengitide treatment did not inhibit proliferation in αvβ3 integrin-negative J3T-1 cells. On 
the other hand, the survival of mice harboring J3T-1 tumors treated with cilengitide was 
significantly longer than control animals. Although the survival of mice harboring J3T-2 
tumors treated with cilengitide was not prolonged, pathologic examination revealed that 
angiogenesis-independent, single-cell infiltration was clearly inhibited by cilengitide. These 
results mean that cilengitide has multi-modal anti-glioma mechanisms. This is the first study 
to show the bimodal mechanisms of the anti-tumor effect of cilengitide on glioma by using 
two animal invasive brain tumor models. 
Cilengitide inhibited the adhesion and proliferation of αvβ3 integrin-positive 
J3T-2 cells in culture. Apoptosis of J3T-2 cells was also induced due to the loss of adherence 
to the plate, which is termed anoikis24. Cilengitide induces anoikis in brain tumor cells by 
inhibiting the phosphorylation of FAK, Src, and Akt17,18. However, the results from our in 
vivo experiments did not show the cytotoxic effect of cilengitide on J3T-2 cells. As shown by 
pathological examination of animal brain tumors treated with cilengitide, apoptotic cell 
numbers did not increase in the integrin-positive J3T-2 brain tumor model. Furthermore, the 
survival of animals harboring J3T-2 gliomas was not prolonged by cilengitide. To our 
knowledge, there is no published data which shows cilengitide-induced anoikis in animal 
brain tumor models. This discrepancy between in vitro and in vivo results might be partly due 
to the difference in the dependency of adhesion molecules and the microenvironment. Many 
adhesion molecules other than αvβ3 integrin, such as cadherins and L1, might be involved in 
cell-cell or cell- extracellular matrix (ECM) adhesion in situ compared with the in vitro 
environment25,26. Therefore, blockade of only αvβ3 integrin cannot induce complete 
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detachment of cells from surrounding tissues and subsequent anoikis. 
Angiogenesis is the formation of new blood vessels by the rerouting or remodeling of 
existing ones, and is the primary method of vessel formation in gliomas. In this study, the 
efficient inhibition of angiogenesis was shown by the tube formation assay of HUVECs in 
vitro. Furthermore, prolonged survival after cilengitide administration was shown in animals 
harboring J3T-1 brain tumors, an angiogenesis-dependent invasive glioma model, but not in 
J3T-2 tumors, an angiogenesis-independent invasive glioma model. Yamada et al. reported 
that cilengitide is highly effective in suppressing blood vessel growth, thereby inhibiting the 
orthotopic growth of human GBM cells in animals27. Angiogenesis requires three distinct 
steps: 1) blood vessel breakdown; 2) degradation of the vessel basement membrane and the 
surrounding ECM; and 3) migration of endothelial cells and the formation of new blood 
vessels3. During the third step, endothelial cells proliferate and begin to migrate toward tumor 
cells expressing pro-angiogenic compounds. Endothelial cell activation up-regulates the 
expression of cell surface adhesion/migration molecules, especially αvβ3 integrin, which 
results in an enhancement of endothelial cell adhesion and migration12,13. Cilengitide might 
prevent the third step of angiogenesis and reduce the size of tumor vessels. Thus, the 
anti-angiogenic effects of cilengitide are likely the main mechanism inhibiting angiogenic 
J3T-1 tumor growth.  
Previously it was reported that there is a shift from the angiogenic to the invasive 
phenotype after anti-angiogenic therapy with use of an anti-VEGF antibody28-31. Invasion is 
another target for glioma therapy and glioma cell invasion requires four distinct steps: 1) 
detachment of invading cells from the primary tumor mass; 2) adhesion to the ECM; 3) 
degradation of the ECM; and 4) cell motility and contractility3. During the second step, 
integrins allow glioma cells to adhere to the ECM. αvβ3 integrin, which binds to fibronectin, 
vitronectin, and tenascin-C in the ECM, plays a central role in glioma invasion15. Platten et al. 
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reported that inhibition of αvβ3 integrin decreased glioma cell motility in vitro32. Cilengitide 
might inhibit this second step, thereby suppressing the invasiveness of the glioma. This is the 
first study to show that cilengitide suppresses the angiogenesis-independent, single-cell 
infiltration of glioma cells in the animal J3T-2 brain tumor model. However, cilengitide had 
no survival benefit on J3T-2 brain tumors. This was because cilengitide had little direct 
cytotoxic effect on tumor cells in situ. 
In the invading front of the glioma, most of the arteries have an intact blood-brain 
barrier (BBB) because single cell invasion is angiogenesis-independent20. Therefore, drugs 
must pass through the normal BBB to exert anti-invasive effects on invading cells. According 
to our results treating J3T-2 brain tumors with cilengitide, the drug apparently passes through 
the normal BBB. In a North American Brain Tumor Consortium (NABTC) study, increased 
intra-tumoral cilengitide levels were shown in patients with glioblastoma when cilengitide 
was administered 24 h before surgical debulking. This study confirms that cilengitide is 
effectively delivered into primary human GBM tumors33.  
 To analyze the mechanisms of angiogenesis and invasion of gliomas, and 
anti-glioma effects of drugs which target them, animal models which show angiogenic tumor 
growth or diffuse invasive growth are required. However, most of the conventional animal 
models show angiogenic tumor growth but fail to mimic the diffuse invasiveness of human 
glioma3. Therefore, analysis of the invasive ability of glioma has depended on in vitro 
evaluation systems. We have established two novel invasive animal glioma models, J3T-1 and 
J3T-2, from the same parental cells that separately reflect these two invasive phenotypes of 
human malignant gliomas20,4. J3T-1 gliomas demonstrate angiogenesis-dependent invasive 
growth that is limited to the perivascular space of newly developed blood vessels. On the 
other hand, J3T-2 gliomas showed angiogenesis-independent, diffusely invasive growth. The 
expression levels of integrins are also different between these models; J3T-1 is αvβ3 
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integrin-negative, while J3T-2 is αvβ3 integrin-positive. 
These models were used to investigate the anti-angiogenic and anti-invasion effects of 
cilengitide separately. The most notable characteristics of our models, which make them ideal 
for studying cilengitide, are as follows. First, J3T-1 and J3T-2 brain tumor models 
histologically recapitulate both the invasive and angiogenic phenotypes observed in human 
glioma. Human gliomas consist of mixtures of these phenotypic subclones20. To clarify the 
anti-glioma mechanisms, models that exhibit each phenotype separately are needed. Second, 
J3T-1 and J3T-2 brain tumor models are easily reproducible. Third, they consist of subclones 
established from the same parental cell. Thus, they should have similar genetic backgrounds 
(T Maruo et al., Proteomics-based analysis of invasion-related proteins in malignant gliomas, 
submitted). 
In this study, the anti-invasive effect of cilengitide was shown in animal brain tumor 
models. Also, the lack of a direct cytotoxic effect of cilengitide was demonstrated in animal 
models. Yamada et al. tested cilengitide in a U87 brain tumor model in mice27. Since U87 
cells show well-demarcated, angiogenic, and non-invasive growth in vivo, Yamada and 
colleagues could only examine the anti-angiogenic effect of cilengitide, but could not test an 
anti-invasive effect or a cytotoxic effect. Therefore, an in vivo evaluation system such as our 
paired invasive glioma models is necessary for the evaluation of novel therapeutic agents. 
The formation of abnormal tumor vasculature and single-cell invasion into normal 
brain parenchyma are major reasons for the resistance of malignant glioma to conventional 
treatments. Our results showed that cilengitide exerts a bimodal anti-glioma effect with 
anti-angiogenic and anti-invasive effects. Therefore, cilengitide holds promise as a glioma 
therapy in the clinical setting.  
There have been several reports that showed preliminary results of phase I or II study 
of cilengitide for recurrent or newly diagnosed malignant glioma. Cilengitide monotherapy or 
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combination treatment with radiation and/or temozolomide is well tolerated and exhibits 
modest anti-tumor activity34. 
Bevacizumab, another anti-angiogenic agent, is a humanized monoclonal antibody 
against vascular endothelial growth factor that demonstrates a strong anti-angiogenic effect in 
gliomas. However, bevacizumab induces a phenotypic shift in the glioma from angiogenic to 
diffusely invasive tumors leading to therapy-resistant tumor progression28-31. According to 
results from a limited number of studies, such phenotypic shift is not reported after 
cilengitide treatment. This might be partly because of cilengitide’s bimodal anti-angiogenic 
and anti-invasive effects.  
According to our results, cilengitide has a strong anti-tumor effect which is mainly 
dependent on the anti-angiogenic and anti-invasive effects but has little, if any, direct 
cytotoxic effect on glioma cells. Therefore, combination therapy with cytotoxic therapeutics, 
e.g., radiation therapy, other chemotherapy, or oncolytic virus therapy, would be effective. 
Alghisi et al. demonstrated that cilengitide elicits signaling events that disrupt vascular 
endothelial (VE)-cadherin localization at cellular contacts and increases the permeability of 
the endothelial monolayer. Therefore, the effects of cilengitide on endothelial cells make it a 
potentially well-suited drug to be combined with chemotherapeutic agents to improve drug 
delivery18. Several preclinical studies have shown an enhanced anti-tumor effect of 
cilengitide when administered in combinatorial therapeutic regimens9,35-37. The 
anti-angiogenic effect of cilengitide also may enhance combined treatments. Mikkelsen et al. 
showed cilengitide did not influence the effect of radiation on U251 glioma cells but strongly 
amplified effects on endothelial cell survival in vitro. They also showed cilengitide treatment 
dramatically amplified the efficacy of radiation therapy in an animal glioma model38. 
Kurozumi and colleagues demonstrated the enhanced therapeutic efficacy of an oncolytic 
virus on experimental glioma with cilengitide pretreatment39. They showed oncolytic virus 
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therapy-induced changes in tumor microenvironment, such as increased tumor vascular 
permeability, leukocyte infiltration, and inflammatory cytokines, were inhibited by 
pretreatment with a single dose cilengitide. 
 
Conclusions 
In conclusion, our results indicate that cilengitide exerts a phenotypic anti-tumor effect by 
inhibiting tumor angiogenesis and tumor cell invasion. These two mechanisms are clearly 
shown by the experimental treatment of two different animal invasive glioma models.  
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Figure legends 
Fig. 1. In vitro and in vivo immunohistochemical analysis of αvβ3 integrin expression in 
J3T-1 and J3T-2 cells. Immunofluorescence of αvβ3 integrin in cultured cells was negative in 
J3T-1 cells (A) and positive on the surface of J3T-2 cells (B). Scale bar = 50 μm. 
Immunohistochemical staining for αvβ3 integrin in brain slices revealed that the J3T-1 
glioma cells were negative for αvβ3 integrin, yet the endothelial cells of dilated tumor vessels 
were positive (C). J3T-2 glioma cells were diffusely positive for αvβ3 integrin (D). Scale bar 
= 50 μm. 
 
Fig. 2. Effects of cilengitide on tube formation. HUVECs co-cultured with fibroblasts and 
VEGF (10 ng/mL) without cilengitide (A) or with cilengitide (0.1, 0.5, 1.0 μM) (B-D) or 
suramin (50 μM) (E) for ten days. The length of tube-like structures was measured 
quantitatively using an image analyzer. The tube length was significantly shortened with 
cilengitide treatment in a concentration-dependent manner (*P = 0.0062, **P = 0.0089). 
(mean ± SE, n = 6) 
 
Fig. 3. Direct cytotoxic effects of cilengitide on the J3T-1 and J3T-2 glioma cells in culture. 
Morphological changes were observed after cilengitide treatment (0.1, 0.5, or 1.0 μM) in a 
dose-dependent manner. Some of the J3T-1 cells became spherical but did not detach from 
the plate (upper panel in A). J3T-2 cells become spherical and agglutinated. Some of the 
deformed cells detached from the plate (lower panel in A). Deformed cells were stained red 
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by TUNEL treatment in J3T-2 cells (lower panel in B), but not in J3T-1 cells (upper panel in 
B). A significant inhibitory effect on the proliferation of J3T-2 cells was observed (*P < 
0.005), but was not seen in J3T-1 cells (P = 0.992) (C). (mean ± SE, n = 6) 
 
Fig. 4. Anti-angiogenic effects of cilengitide on the J3T-1 gliomas in rats. Macroscopic 
examinations Low magnification of HE staining of control tumors (A) and cilengitide-treated 
tumors (B) revealed the same invasive pattern of cluster formation around dilated 
neovasculature. However, the spread of the invasion clusters was significantly smaller in 
animals treated with cilengitide compared with control animals. Scale bar = 2.0mm. When 
examined with immunofluorescence staining (vascular: RECA-1, red; nuclei: DAPI, blue), 
the diameter of the tumor clusters and its core vessels in cilengitide-treated animals (D) was 
smaller than that in untreated animals (C). Scale bar = 100 μm. The quantitative analysis of 
the diameter of the tumor clusters (E) and its core vessels (F) revealed a significant decrease 
in cilengitide-treated animals compared with control animals (P＜0.005). (mean ± SE, n = 3) 
 
Fig. 5. Anti-invasive effects of cilengitide on the J3T-2 gliomas in rats. HE staining of 
control tumors (A) and cilengitide-treated tumors (B) revealed that tumor cells gradually 
dispersed from the tumor center to the normal brain parenchyma with a cell density gradient 
in both tumors. Scale bar = 2 mm. Immunofluorescence staining (vascular endothelial cells: 
RECA-1, red; nuclei: DAPI, blue) of control tumors (C) and cilengitide-treated tumors (D) 
revealed that the tumor borders of the treated tumors were more evident. Scale bar = 500 μm. 
The cell density was higher at the center of the tumor and lower at the periphery of the 
infiltration area in animals treated with cilengitide compared with control animals (E). There 
were no significant differences in the cell numbers in the examined areas (F) (P = 0.27). 
(mean ± SE, n = 3) 
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Fig. 6. Cytotoxic effects of cilengitide on the J3T-1 and J3T-2 rat brain tumors. A 
subpopulation of apoptotic cells were visualized by TUNEL staining (apoptotic cells: TMR 
red; nuclei: DAPI, blue) of J3T-1 control tumors (A), J3T-1 cilengitide-treated tumors (B), 
J3T-2 control tumors (C), and J3T-2 cilengitide-treated tumors (D). Scale bar = 100 μm. The 
quantitative analysis of the number of the apoptotic cells/HPF in J3T-1 tumors (E) and J3T-2 
tumors (F) revealed no significant difference between control and cilengitide-treated animals 
(J3T-1, P=0.5972; J3T-2, P=0.4233). (mean ± SE, n = 6) 
 
Fig. 7. Survival of athymic mice harboring J3T-1 or J3T-2 brain tumors treated with 
cilengitide. Kaplan–Meier survival analysis of athymic mice harboring intracranial J3T-1 (A) 
and J3T-2 (B) brain tumors treated with cilengitide or PBS. The survival time of J3T-1 glioma 
mice was significantly prolonged by the intraperitoneal injection of cilengitide (A) (P < 
0.005) while the survival of J3T-2 glioma mice was not prolonged (B) (P = 0.6889). 
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